Felvizumab

Modify Date: 2024-04-06 19:07:45

Felvizumab structure	Common Name	Felvizumab
	CAS Number	167747-20-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Felvizumab

Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2].

Name	Felvizumab

Description	Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> RSV
Target	EC50: 0.49 μg/mL (RSV Type A in microneutralization assay), 0.95 μg/mL (RSV Type A in fusion inhibition assay)[2]
In Vitro	Felvizumab (RSHZ19) (2 h or 4 h) 抑制 RSV A 型，微量中和试验中 EC50 为 0.49 ± 0.37 μg/mL，融合抑制试验中 EC50 为 0.95 ± 0.13 μg/mL[2]。
In Vivo	Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) 在 RSV 感染大鼠模型中对 A 和 B 亚型 RSV 有效[2]。 Animal Model: Cotton rats, RSV infection model[2] Dosage: 0.625, 1.25, 2.5, and 5.0 mg/kg Administration: Intramuscular injection, 1 day before infection Result: Significantly reduced lung RSV titer.
References	[1]. Fenton C, et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6(3):177-97. [2]. Johnson S, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999 Jul;180(1):35-40.

No Any Chemical & Physical Properties